Скачать или смотреть ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022

Reporting from the ASCO Genitourinary Symposium 2022, Fred Saad provides an overview of practice changing studies with combination therapy in advanced prostate cancer. He features the improved rPFS demonstrated in PROpel and MAGNITUDE with a combination of PARPi with abiraterone or AAP in patients with mCRPC. He also discusses reduction in the risk of death by adding darolutamide to ADT + docetaxel in patients with mHSPC and other endpoints fovouring the triplet therapy.

Abstracts:
11 - PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). - Fred Saad, USA
12 - Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations. - Kim Chi, USA
13 - Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial. - Matthew Smith, USA

Produced by the European Society for Medical Oncology
http://oncologypro.esmo.org